Table 3.
Percentage of caspase-3 activity of glioblastoma (C6) cells after CCDP (cisplatin), ε-VNF (ε-viniferin) and CDDP/ε-VNF (cisplatin + ε-viniferin) treatment at different times and concentrations
| 12 h | 24 h | 48 h | 72 h | |||||
|---|---|---|---|---|---|---|---|---|
| Viability (%) | Caspase activity (%) | Viability (%) | Caspase activity (%) | Viability (%) | Caspase activity (%) | Viability (%) | Caspase activity (%) | |
| Control | 99.6 | 0.4 | 95.3 | 4.6 | 94.7 | 5.3 | 93.9 | 6.0 |
| CDDP (35 µΜ) | 99.6 | 0.4 | 91.2 | 8.8 | 95.5 | 4.5 | 85.6 | 14.4 |
| CDDP (5 μM) | 99.7 | 0.3 | 94.7 | 5.3 | 89.4 | 10.6 | 95.3 | 14.6 |
| ε-VNF (130 μM) | 99.4 | 0.6 | 86.1 | 13.9 | 94.4 | 5.6 | 85 | 14.9 |
| ε-VNF (95 μM) | 99.2 | 0.8 | 96.1 | 3.9 | 95.7 | 4.4 | 84.5 | 15.4 |
| CDDP/ε-VNF (16.25 + 127.5 μM) | 99.3 | 0.7 | 91.0 | 9.0 | 98.1 | 1.9 | 89.6 | 10.3 |
| CDDP/ε-VNF (13.25 + 95 μM) | 99.4 | 0.6 | 93.7 | 6.3 | 95.7 | 4.4 | 84.5 | 15.5 |